Flu season should return Sanofi to double-digit vaccines growth, CEO says

Sanofi CEO Chris Viehbacher

Thanks to supply limitations in the U.S. that spurred a near-30% drop in adult booster vaccines, Sanofi ($SNY) reported Q2 vaccines sales down 0.4% overall. But its flu business posted big gains, ballooning 18.9% to €59 million ($78.9 million)--and CEO Chris Viehbacher says he expects that trend to continue. The helmsman forecast a "very successful" flu season in the U.S. that would help return the unit to double-digit growth in the second half of this year, noting only that that market was becoming tougher on pricing, Reuters reports. "That bears watching and would be my only point of caution for the future," Viehbacher said (as quoted by the news service). Release (PDF) | Report